% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Waheed:282689,
      author       = {D.-E.-N. Waheed and F. R. Burdier and C. Eklund and I.
                      Baussano and F. C. Mariz$^*$ and L. Téblick and N. Mugo and
                      D. Watson-Jones and M. Stanley and M. Baay and A. Vorsters},
      title        = {{A}n update on one-dose {HPV} vaccine studies,
                      immunobridging and humoral immune responses - {A} meeting
                      report.},
      journal      = {Preventive Medicine Reports},
      volume       = {35},
      issn         = {2211-3355},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01835},
      pages        = {102368},
      year         = {2023},
      abstract     = {The 12th HPV Prevention and Control meeting was held on
                      June 2-3, 2022, in Antwerp, Belgium. This technical meeting
                      focused on several topics. This report summarises the
                      discussions and lessons learned on two topics: an update on
                      one-dose HPV vaccination studies and humoral immune
                      responses upon HPV vaccination. Long-term follow-up studies
                      from Costa Rica (eleven years) and India (ten years) report
                      stable levels of antibodies after a single HPV vaccination.
                      High vaccine effectiveness against incident persistent HPV
                      16/18 infection was seen in India $(95.4\%,$ 85.0-99.9) ten
                      years postvaccination and in Kenya $(97.5\%,$ 81.7-99.7)
                      eighteen months postvaccination, an important observation in
                      a setting with a higher HPV prevalence. The potential impact
                      of HPV vaccination using a one-dose schedule in India was
                      modelled and showed that implementation of one-dose schedule
                      can contribute towards achieving WHO Cervical Cancer
                      elimination goals. These data support the WHO SAGE
                      recommendations for adopting a one-dose schedule for females
                      aged 9-20 years. Immunobridging studies were discussed
                      during the meeting. General agreement was reached that when
                      thoughtfully applied, they can support and accelerate the
                      expanded use of HPV vaccine with new vaccine schedules, age
                      cohorts, or vaccine formulations. Internationally
                      standardised measurements of HPV immune responses important
                      for the progress of HPV vaccinology field. Humoral immune
                      responses upon HPV vaccination plateau at 24 months
                      regardless of number of doses, therefore, data should be
                      analysed after at least 24 months of follow-up to bridge
                      studies accurately.},
      keywords     = {Clinical trials (Other) / Human papilloma virus (Other) /
                      Humoral immune responses (Other) / Immunobridging (Other) /
                      Meeting report (Other) / One dose (Other) / Schedule (Other)
                      / Vaccination (Other)},
      cin          = {F035},
      ddc          = {610},
      cid          = {I:(DE-He78)F035-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37680853},
      pmc          = {pmc:PMC10480621},
      doi          = {10.1016/j.pmedr.2023.102368},
      url          = {https://inrepo02.dkfz.de/record/282689},
}